

Virinchi Hospitals, MedGenome tie up

Y V PHANI RAJ

Hyderabad

Hyderabad-based Virinchi Hospitals, a subsidiary of IT company Virinchi has entered into a strategic collaboration with MedGenome, a genomics-based diagnostics and research company for molecular diagnostics.

As part of the collaboration, Virinchi will offer MedGenome's tests in the cardiology, ophthalmology, oncology, neurology, nephrology, diabetes, dermatology and haematology besides other conditions. It will also include non-invasive prenatal tests, which will define genetic health.

MedGenome offers over 400 genetic tests across disease areas. It is connected to 500 hospitals for diagnostics and has established more than 50 research collaborations. Virinchi is a 600-bed tertiary healthcare provider.

Dr Chirantan Bose, V-P, Clinical Services, MedGenome, said, "We are



JOINING HANDS: Virinchi Hospitals medical director Dr Murty Nekkanti (centre) and MedGenome V-P Dr Chirantan Bose (right) announcing the partnership in Hyderabad.

looking forward to this partnership for bringing affordable and high quality genetic testing to the patients of Virinchi hospitals.

MedGenome is helping in reduce the costs of previously expensive genetic tests, and empowering clinicians with actionable insights to provide better outcomes for their patients."

He told *Telangana Today*, "Virinchi wants to use mo-

lecular genomics as part of its overall treatment protocol. From early stage, patients will be able to take advantage of the tests available. We want to create a molecular genomics clinical lab which will significantly improve the patient interface. While on one hand the prognosis and treatment can be specific and accurate, on the other hand it brings down the

overall treatment cost using advanced technologies. We are a reference lab with clinical expertise in genomics and our collaboration with Virinchi will be continual."

Commenting on the partnership, Dr Murty Nekkanti, medical director, Virinchi Hospitals, said, "The aim of this collaboration is to help the clinician with molecular information for accurate as well as precise diagnosis, prognosis and management of multitude of diseases that have genetic basis."

"And, genetic testing has gradually been gaining prominence and significance in terms in effectively diagnosing and managing many rare to common diseases such as Spinal muscular atrophy, Huntington's disease, and Inborn errors of metabolism. Our collaboration with partners like Medgenome shall certainly keep us in a favourable position to offer molecular testing services more competently to our patients," he said.